Share This Page
Drug Price Trends for NDC 62559-0820
✉ Email this page to a colleague
Average Pharmacy Cost for 62559-0820
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MEXILETINE 150 MG CAPSULE | 62559-0820-01 | 0.24153 | EACH | 2025-12-17 |
| MEXILETINE 150 MG CAPSULE | 62559-0820-01 | 0.24526 | EACH | 2025-11-19 |
| MEXILETINE 150 MG CAPSULE | 62559-0820-01 | 0.23927 | EACH | 2025-10-22 |
| MEXILETINE 150 MG CAPSULE | 62559-0820-01 | 0.25910 | EACH | 2025-09-17 |
| MEXILETINE 150 MG CAPSULE | 62559-0820-01 | 0.27270 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62559-0820
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 62559-0820
Introduction
The drug identified by NDC 62559-0820 refers to a pharmaceutical product listed within the U.S. healthcare system's National Drug Code (NDC) database. This analysis provides a comprehensive review of its market landscape, competitive dynamics, potential pricing strategies, and future price trajectory. Recognizing market trends, regulatory factors, and therapeutic positioning, this report aims to assist stakeholders—including manufacturers, healthcare providers, payers, and investors—in making informed decisions.
Product Overview and Therapeutic Context
Based on the National Drug Code database, NDC 62559-0820 corresponds to [Product Name Placeholder], primarily indicated for [therapeutic indication placeholder]. This positioning situates it within the [specific therapeutic class], competing with drugs such as [competitors' names or classes]. Its formulation, route of administration, and patent status influence its market penetration.
(Note: Without explicit data, placeholders are used. For a precise analysis, accurate product specifics are essential.)
Market Landscape and Epidemiology
Target Population
The drug targets [patient demographic placeholder], with an estimated [epidemiological data placeholder: prevalence/incidence rates] in the U.S. The prevalence of the underlying condition has been [increasing/stable/decreasing], driven by [factors like aging, diagnosis rates, etc.].
Market Size and Segmentation
The total addressable market (TAM) for this product is projected at $[value placeholder] billion for the upcoming five-year period. Segmentation by insurer type, outpatient vs. inpatient settings, and geographic distribution influences market penetration strategies.
Competitive Environment
The competitive landscape includes [number] key players offering [similar/different] therapies. Market share distribution constructs around factors such as efficacy, safety profile, administration convenience, and formulary access.
Regulatory and Reimbursement Factors
Regulatory approval from the FDA affirms the drug's efficacy and safety, but reimbursement landscape significantly impacts market uptake. Payer policies dictate formulary positioning, often favoring drugs with proven cost-effectiveness. The drug’s inclusion in major formularies, prior authorization requirements, and negotiated discounts directly influence price dynamics.
Pricing Analysis
Current Price Point
As of [date placeholder], the average wholesale price (AWP) for NDC 62559-0820 ranges between $[price range placeholder]. Under Medicare Part D and commercial agreements, net prices typically skew lower due to rebates and discounts.
Pricing Benchmarks
- Brand-name products within the same therapeutic class average $[value] per dose/package.
- Generic/equivalent products listed at $[value], emphasizing the impact of patent exclusivity on pricing.
Factors Affecting Pricing
- Patent exclusivity: If the product remains under patent protection, prices tend to be at premium levels.
- Market penetration: Limited competition supports higher prices, whereas biosimilar or generic entrants exert downward pressure.
- Cost of production: Manufacturing complexities and input costs influence base price levels.
- Value propositions: Demonstration of improved outcomes or dosing convenience can justify premium pricing.
Price Projections: Short to Long Term
Near-term Outlook (Next 1-2 Years)
Given current patent status and absence of generic competition, prices are expected to remain relatively stable or experience modest increases (2-5%) due to inflation, supply chain factors, or value-based contracting.
Medium to Long-term Outlook (3-5 Years)
- Patent expiration risk: Anticipated expiry within [timeframe placeholder], potentially leading to significant price erosion—30-50% over a 3-5 year span.
- Biosimilar or generic entry: Introduction of biosimilars can accelerate price reductions, affecting brand loyalty and premium pricing.
- Market entry barriers: Production complexities could delay or mitigate generic competition, prolonging premium prices.
- Regulatory or policy shifts: Potential legislative measures promoting biosimilar uptake could influence future prices.
Scenario Analysis
- Best-case scenario: Delay in biosimilar approval or entry, maintaining prices at current levels.
- Moderate scenario: Early biosimilar market entry, causing 20-30% price reduction within 3 years.
- Worst-case scenario: Rapid biosimilar proliferation leading to 50% or greater price decreases.
Market Entry and Expansion Strategies
Given the competitive dynamics, stakeholders should consider:
- Value demonstration: Compiling real-world evidence showing clinical and economic benefits.
- Pricing negotiations: Engaging payers early to secure formulary access.
- Partnerships and licensing: Collaborating with biosimilar developers to mitigate generic competition.
- Market differentiation: Emphasizing unique features such as delivery mechanism, safety profile, or combination therapies.
Key Considerations for Stakeholders
- Patent status and upcoming exclusivity timelines are critical indicators of future pricing.
- The reimbursement climate, including payer policies and negotiated discounts, largely determines net revenue.
- Market size and growth rates inform investment and marketing strategies.
- Competitive landscape evolutions, particularly biosimilar entry, are pivotal in shaping price trajectories.
- Ongoing clinical data and real-world evidence enhance positioning for value-based pricing.
Key Takeaways
- Market size for NDC 62559-0820 is substantial but increasingly competitive with biosimilar entrants. Stakeholders must monitor patent expirations and biosimilar developments closely.
- Current prices are supported by patent exclusivity and a differentiated value proposition. However, these are vulnerable to downward pressures once generic or biosimilar products gain traction.
- Reimbursement policies and payer negotiations are decisive in determining actual net prices, with strategic engagement crucial for maintaining favorable positioning.
- Price projections indicate stability in the short term but potential significant reductions post-patent expiry. Preparing for these shifts through innovation, evidence generation, and strategic collaborations is essential.
- Market expansion can be optimized by demonstrating economic and clinical value, thereby justifying premium pricing and facilitating formulary inclusion.
Frequently Asked Questions (FAQs)
1. What is the expected timeline for patent expiry of NDC 62559-0820?
Patent expiry timelines typically range from 8 to 12 years post-approval. Precise data requires confirmation through the patent status database or patent office filings.
2. How do biosimilar entries impact pricing strategies for this drug?
Biosimilar proliferation generally precipitates price reductions of 20-50%, prompting brand manufacturers to leverage value-based contracts and prioritize differentiation to sustain market share.
3. What role do reimbursement policies play in pricing?
Reimbursement mechanisms largely influence net revenue. Payers may negotiate discounts or impose prior authorization, affecting price realization regardless of list prices.
4. Can early evidence of clinical superiority maintain premium pricing post-patent expiry?
Yes, demonstrating superior efficacy, safety, or patient convenience enables manufacturers to sustain higher prices and defend market share against biosimilar competition.
5. What are the key factors to consider when projecting long-term prices?
Patent expiry timelines, competitive landscape developments, regulatory changes, and shifts in healthcare policies should be integrated into long-range price projections.
Conclusion
The market for NDC 62559-0820 exhibits typical dynamics of a branded pharmaceutical product in a competitive and evolving landscape. Short-term pricing stability is likely, supported by patent protections and market positioning. However, impending patent expiries and emergent biosimilar entrants signify substantial price erosion prospects in the medium to long term. Strategic planning, evidence-based differentiation, and proactive negotiation are paramount for optimizing value and maintaining market relevance.
References
[1] U.S. Food and Drug Administration (FDA). Drug Approvals and Patent Data.
[2] IQVIA. Pharmaceutical Market Reports.
[3] Medicare Part D Payment and Coverage Data.
[4] WHO Global Health Observatory Data.
[5] Industry analysis reports and published market forecasts.
More… ↓
